Related Experiment Videos
Melphalan-related leukemia in multiple myeloma
Acta Medica Scandinavica
|May 1, 1982
Summary
Multiple myeloma patients can develop acute leukemia, especially after long-term melphalan treatment. Cumulative melphalan dose appears to be a significant risk factor for this secondary malignancy.
Area of Science:
- Hematology
- Oncology
Background:
- Multiple myeloma is a hematologic malignancy.
- Secondary malignancies are a known complication of cancer therapy.
Observation:
- Five cases of multiple myeloma progressing to acute leukemia are presented.
- A preleukemic phase with cytopenias (anemia, leukopenia, thrombocytopenia) was noted.
Findings:
- The incidence of acute leukemia in multiple myeloma was 6%.
- Melphalan therapy exceeding two years raised this incidence to 14%.
- A cumulative melphalan dose of ≥1100 mg correlated with leukemia development.
Implications:
- Long-term melphalan use in multiple myeloma increases the risk of secondary acute leukemia.
- Careful monitoring for preleukemic changes is warranted in patients on prolonged melphalan therapy.
- Dose-response relationship suggests a link between cumulative melphalan exposure and leukemogenesis.